SABR for Oligometastatic Cancer Turns in ‘Acceptable’ Rates of Toxicity
Stereotactic ablative radiotherapy (SABR) treatment for oligometastatic or oligoprogressive cancer appeared to come with “acceptable” rates of toxic effects, according to SABR-5 study results. Among a population of 381 patients in the phase II trial, and with a median follow-up of 25 months, rates of grade 2 or greater toxic effects were observed in 18.6%, […]